Explore groundbreaking studies in medicinal chemistry, drug design methodologies, and therapeutic discovery
Exploring the potential of Empagliflozin, an SGLT2 inhibitor, in preventing Acute Kidney Injury (AKI) based on the landmark EMPA-KIDNEY trial results.